BlackRock Beats Q2 With $12.19 EPS While Elevance Health Raises Full-Year Guidance
BlackRock reported Q2 EPS of $12.19 beating estimates with $7.08B revenue, while Elevance Health posted Q2 EPS of $6.71 and raised full-year guidance, with both results highlighting breadth across US earnings season.
TLDR
- โBlackRock Q2 EPS $12.19 beats with $7.08B revenue and GF Score 93
- โElevance Health EPS $6.71 beats and raises full-year guidance
- โStrong financials and managed care results add to Q2 earnings breadth
Editorial Self-Reviewยท76/100Publish tier
- Two meaningful earnings beats with specific EPS figures
- Sector context and macro implications well-articulated
- Both sources Tier 3 only; no Tier 1 or 2 confirmation
- Specific estimate figures not available to calculate beat percentage
Why this matters
Coverage sentiment: Bullish (2 bullish ยท 0 neutral ยท 0 bearish)
What to watch
- โข BlackRock Q3 AUM inflows and ETF market share versus Vanguard and State Street
- โข Elevance medical loss ratio trajectory into Medicaid redetermination completion
Ripple effects
- โข BlackRock AUM flow data signals sustained institutional risk appetite into Q3
AI-Synthesized news from multiple sources
This article was synthesized by AI from the source articles listed below, reviewed by a second-pass AI quality reviewer, and published by the market.news editorial system. How we do this ยท Editorial standards ยท Report an error
- BlackRock (BLK) reported Q2 EPS of $12.19, beating estimates, with revenue reaching $7.08 billion and a GF Score of 93/100
- Elevance Health (ELV) posted Q2 EPS of $6.71, topping forecasts, and raised its full-year guidance following the strong performance
- Both results reinforce breadth of the current US earnings season, with financial services and managed care sectors outperforming
- Dual Tier 3 sourcing from GuruFocus; independent analyst estimates not yet available for cross-validation
BlackRock delivered a strong Q2 2026 earnings beat with EPS of $12.19 and quarterly revenue of approximately $7.08 billion, driven by continued inflows into its ETF and active fixed income franchises. The world's largest asset manager earned a GF Score of 93 out of 100, reflecting sustained profitability and balance sheet strength. With interest rates remaining elevated, BlackRock has benefited from demand for money market funds and short-duration fixed income products, while its Aladdin technology platform continues to deepen institutional client relationships.
Elevance Health, formerly Anthem, reported Q2 EPS of $6.71 that beat consensus expectations and followed through with a raise to full-year guidance โ a signal of confidence in its medical loss ratio management and commercial enrollment trajectory. The GF Score of 88 out of 100 reflects solid fundamentals for the managed care operator. Elevance has navigated Medicaid redetermination pressures that weighed on peers in recent quarters, and guidance improvement suggests the worst of those enrollment headwinds may be behind the company.
Together, BLK and ELV results illustrate the resilience of earnings across the financial and healthcare services complex in Q2 2026, complementing the broader picture of US corporate profitability holding up even as consumer spending shows early fatigue signals. For macro observers, BlackRock AUM flows are a barometer of investor risk appetite, while Elevance guidance lifts are read as a proxy for healthcare utilization normalization โ both suggest the underlying economy is absorbing rate pressures without severe demand destruction entering the second half.
Sources: GuruFocus. Market news synthesis for informational purposes only.
Market Intelligence Panel
Sentiment
BullishCoverage
livesources covering this story
Live Price
FOREXCOM:SPXUSD๐ Key Numbers
๐ Ripple Effects
- โธBlackRock AUM flow data signals sustained institutional risk appetite into Q3
- โธElevance guidance raise eases managed care sector re-rating concerns
- โธStrong financial services earnings support broader S&P 500 earnings revision cycle
๐ญ What to Watch Next
PRO- โธBlackRock Q3 AUM inflows and ETF market share versus Vanguard and State Street
- โธElevance medical loss ratio trajectory into Medicaid redetermination completion
- โธBoth stocks reaction vs GF Score implied valuation gap
Market news synthesis. Not financial advice. Sources cited above.
How the Story Spread
2 publishers covering this story
AI synthesis of every source listed below. Tier 1 = wire services (AP, Reuters via wire, Bloomberg, official central banks). Tier 2 = major financial publishers. Tier 3 = niche / specialist outlets. Click any card to read the original article.
โ Tier 3 โ Niche & specialist
Is BlackRock Inc (BLK) Undervalued After Q2 Earnings Beat? EPS at $12.19 and Revenue at $7. ...
Financial Highlights from the Latest Earnings Filing Related Stocks: BLK,
Is Elevance Health Inc (ELV) Undervalued After Q2 Earnings? EPS of $6. ...
Company Raises Full-Year Guidance Following Strong Performance Related Stocks: ELV,
Get the Daily Briefing
Pre-market analysis every morning at 6am ET. Free.
Was this article useful?
Anonymous ยท helps us tune the editorial system
More ๐บ๐ธ United States Stories
Electrovaya Surges 55% After Announcing Amazon Partnership for Battery Technology
Electrovaya (ELVA) surged 55% after announcing a partnership with Amazon for its lithium-ion industrial battery technology, providing a major commercial validation that could open fleet electrification contracts across the logistics sector.
Jul 16, 2026
๐บ๐ธ United StatesGoldman Sachs Q2 Earnings Surge as Investment Banking Revenue Jumps 55%
Goldman Sachs reported strong Q2 2026 earnings headlined by a 55% surge in investment banking revenue, confirming the IB cycle has turned decisively with M&A advisory, IPO underwriting, and debt capital markets all accelerating.
Jul 16, 2026
๐บ๐ธ United StatesNepra Foods Clears Lease Hurdle for Artesian Fusion Acquisition in Plant-Based Expansion
Nepra Foods (NPRFF) secured lease approval for its Artesian Fusion acquisition, clearing a key hurdle in the transaction and reducing deal completion risk for investors tracking the plant-based food company.
Jul 16, 2026